Repligen | RGEN - Operating Profit

Stock Price
117.60
Daily Change
3.54 3.10%
Monthly
2.87%
Yearly
-18.76%
Q2 Forecast
115.08

Repligen reported $19.97M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agilent USD 353M 90M Dec/2025
Align Technology USD 224.71M 40.06M Dec/2025
Bio Techne USD 54.46M 6.8M Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Bruker USD 76.3M 7.6M Dec/2025
Charles River Laboratories USD 75.82M 57.98M Dec/2025
Danaher USD 1.34B 158M Mar/2026
Dentsply International USD 538M 26M Dec/2025
General Electric Aerospace USD 2.32B 549M Mar/2026
Henry Schein USD 186M 12M Dec/2025
Illumina USD 256M 6M Dec/2025
IQVIA Holdings USD 2.68B 2.1B Dec/2025
Mettler Toledo International USD 351.93M 57.73M Dec/2025
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Repligen USD 19.97M 7.29M Dec/2025
Revvity USD 145.83M 47.49M Dec/2025
Standard Biotools USD -21.92M 1.55M Dec/2025
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Waters USD 270.52M 78.4M Dec/2025
West Pharmaceutical Services USD 177.1M 14.6M Mar/2026